Hugel - Public Comps and Valuation Multiples

Hugel Overview

About Hugel

Hugel Inc is a biopharmaceutical company. It is in the business of manufacturing of biopharmaceuticals. The company's primary products are Botulinum toxin, Hyaluronic acid filler, and Cosmetics. It develops and promotes its products under the brand name of Wellage. The firm has manufacturing facilities in Shinbuk and Geodu.

Founded

2001

HQ

Employees

n/a

Website

hugel.co.kr

Sectors

Biopharmaceuticals
Nutraceuticals & Cosmeceuticals
BioTech

Financials

LTM Revenue $298M

LTM EBITDA $156M

EV

$1.6B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Hugel Financials

As of September 2025, Hugel reported last 12-month revenue of $298M and EBITDA of $156M.

In the same period, Hugel generated $234M in LTM gross profit and $111M in net income.

See Hugel valuation multiples based on analyst estimates

Hugel P&L

In the most recent fiscal year, Hugel reported revenue of $261M and EBITDA of $127M.

Hugel expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Hugel valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$298M	XXX	$261M	XXX	XXX	XXX
Gross Profit	$234M	XXX	$201M	XXX	XXX	XXX
Gross Margin	79%	XXX	77%	XXX	XXX	XXX
EBITDA	$156M	XXX	$127M	XXX	XXX	XXX
EBITDA Margin	52%	XXX	49%	XXX	XXX	XXX
EBIT	$145M	XXX	$116M	XXX	XXX	XXX
EBIT Margin	49%	XXX	45%	XXX	XXX	XXX
Net Profit	$111M	XXX	$95.0M	XXX	XXX	XXX
Net Margin	37%	XXX	36%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Hugel including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $298M. EBITDA for the last twelve months was $156M. In the most recent fiscal year, Hugel achieved $261M in revenue and $127M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$298M	Analyst estimates available to subscribers	$261M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$234M	Analyst estimates available to subscribers	$201M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	78.5% gross margin	Analyst estimates available to subscribers	77.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$156M	Analyst estimates available to subscribers	$127M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	52.3% EBITDA margin	Analyst estimates available to subscribers	48.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$145M	Analyst estimates available to subscribers	$116M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	48.6% EBIT margin	Analyst estimates available to subscribers	44.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$111M	Analyst estimates available to subscribers	$95.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	37.3% net profit margin	Analyst estimates available to subscribers	36.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Hugel

This financial data table provides comprehensive performance metrics for Hugel, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Hugel generated $298M in revenue over the last twelve months.
The company achieved $156M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $234M.
Net income over the last twelve months reached $111M.

Fiscal Year Performance

In the most recent fiscal year, Hugel reported $261M in total revenue.
Fiscal year EBITDA was $127M.
The company maintained a gross profit margin of 77.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 48.6%.
Net profit margin reached 36.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Hugel. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Hugel Stock Performance

Hugel has current market cap of KRW 2.80T (or $2.0B), and EV of KRW 2.35T (or $1.6B).

Market Cap Evolution

Hugel Stock Data

As of October 17, 2025, Hugel's stock price is KRW 259000 (or $181).

See Hugel trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.6B	$2.0B	XXX	XXX	XXX	XXX	$9.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Hugel Valuation Multiples

Hugel's trades at 6.3x EV/Revenue multiple, and 12.9x EV/EBITDA.

See valuation multiples for Hugel and 15K+ public comps

Hugel Financial Valuation Multiples

As of October 17, 2025, Hugel has market cap of $2.0B and EV of $1.6B.

Equity research analysts estimate Hugel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Hugel has a P/E ratio of 17.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.0B	XXX	$2.0B	XXX	XXX	XXX
EV (current)	$1.6B	XXX	$1.6B	XXX	XXX	XXX
EV/Revenue	5.5x	XXX	6.3x	XXX	XXX	XXX
EV/EBITDA	10.5x	XXX	12.9x	XXX	XXX	XXX
EV/EBIT	11.3x	XXX	14.1x	XXX	XXX	XXX
EV/Gross Profit	7.0x	XXX	n/a	XXX	XXX	XXX
P/E	17.6x	XXX	20.6x	XXX	XXX	XXX
EV/FCF	18.0x	XXX	20.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Hugel Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Hugel Margins & Growth Rates

Hugel's last 12 month revenue growth is 18%

Hugel's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Hugel's rule of 40 is 65% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Hugel's rule of X is 96% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Hugel and other 15K+ public comps

Hugel Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	18%	XXX	18%	XXX	XXX	XXX
EBITDA Margin	52%	XXX	49%	XXX	XXX	XXX
EBITDA Growth	22%	XXX	25%	XXX	XXX	XXX
Rule of 40	65%	XXX	66%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	96%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	15%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	2%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	32%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial